Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children

Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children

Abstract Introduction Tapinarof is a topical aryl hydrocarbon receptor (AhR) agonist in development for the treatment of atopic dermatitis (AD). In two phase 3 trials (ADORING 1 and 2), tapinarof cream 1% once daily (QD) demonstrated significant efficacy and was well tolerated in patients down to ag...

Full description

Saved in:
Bibliographic Details
Main Authors: Eric L. Simpson, Adelaide A. Hebert, John Browning, Rocco T. Serrao, Howard Sofen, Philip M. Brown, Stephen C. Piscitelli, David S. Rubenstein, Anna M. Tallman
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-01-01
Series:Dermatology and Therapy
Subjects:
Atopic dermatitis
Family impact
Patient-reported outcomes
Quality of life
Sleep improvement
Tapinarof cream 1% once daily
Online Access:https://doi.org/10.1007/s13555-024-01318-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s13555-024-01318-6

Similar Items